Published in J Natl Cancer Inst on July 18, 2001
G-quadruplex formation within the promoter of the KRAS proto-oncogene and its effect on transcription. Nucleic Acids Res (2006) 3.09
High resolution melting analysis for the rapid and sensitive detection of mutations in clinical samples: KRAS codon 12 and 13 mutations in non-small cell lung cancer. BMC Cancer (2006) 2.97
Ras in cancer and developmental diseases. Genes Cancer (2011) 2.68
Astrocyte elevated gene-1 (AEG-1) is a target gene of oncogenic Ha-ras requiring phosphatidylinositol 3-kinase and c-Myc. Proc Natl Acad Sci U S A (2006) 2.38
High resolution melting analysis for rapid and sensitive EGFR and KRAS mutation detection in formalin fixed paraffin embedded biopsies. BMC Cancer (2008) 2.16
Germline missense mutations affecting KRAS Isoform B are associated with a severe Noonan syndrome phenotype. Am J Hum Genet (2006) 1.78
Site-specific monoubiquitination activates Ras by impeding GTPase-activating protein function. Nat Struct Mol Biol (2012) 1.76
Bench to bedside and back again: molecular mechanisms of alpha-catenin function and roles in tumorigenesis. Semin Cancer Biol (2007) 1.76
Protein kinase Ciota is required for Ras transformation and colon carcinogenesis in vivo. J Cell Biol (2004) 1.63
Noonan syndrome: clinical aspects and molecular pathogenesis. Mol Syndromol (2010) 1.60
Sorafenib inhibits signal transducer and activator of transcription 3 signaling associated with growth arrest and apoptosis of medulloblastomas. Mol Cancer Ther (2008) 1.56
Disorders of dysregulated signal traffic through the RAS-MAPK pathway: phenotypic spectrum and molecular mechanisms. Ann N Y Acad Sci (2010) 1.54
Activated Kras, but not Hras or Nras, may initiate tumors of endodermal origin via stem cell expansion. Mol Cell Biol (2008) 1.53
Investigation of the effect of the farnesyl protein transferase inhibitor R115777 on isoprenylation and intracellular signalling by the prostacyclin receptor. Br J Pharmacol (2004) 1.45
Dual cancer-specific targeting strategy cures primary and distant breast carcinomas in nude mice. Proc Natl Acad Sci U S A (2005) 1.41
Targeting the MAPK pathway in melanoma: why some approaches succeed and other fail. Biochem Pharmacol (2010) 1.36
Upregulation of the Catalytic Telomerase Subunit by the Transcription Factor ER81 and Oncogenic HER2/Neu, Ras, or Raf. Mol Cell Biol (2004) 1.31
Lung cancer. 9: Molecular biology of lung cancer: clinical implications. Thorax (2003) 1.28
The synergistic combination of the farnesyl transferase inhibitor lonafarnib and paclitaxel enhances tubulin acetylation and requires a functional tubulin deacetylase. Cancer Res (2005) 1.28
Clinical pharmacogenomic testing of KRAS, BRAF and EGFR mutations by high resolution melting analysis and ultra-deep pyrosequencing. BMC Cancer (2011) 1.27
Roles of the PI-3K and MEK pathways in Ras-mediated chemoresistance in breast cancer cells. Br J Cancer (2003) 1.25
While K-ras is essential for mouse development, expression of the K-ras 4A splice variant is dispensable. Mol Cell Biol (2003) 1.24
Activated KrasG¹²D is associated with invasion and metastasis of pancreatic cancer cells through inhibition of E-cadherin. Br J Cancer (2011) 1.21
Mutational analysis of EGFR and K-RAS genes in lung adenocarcinomas. Virchows Arch (2005) 1.20
Rapamycin potentiates transforming growth factor beta-induced growth arrest in nontransformed, oncogene-transformed, and human cancer cells. Mol Cell Biol (2002) 1.18
A role for K-ras in conferring resistance to the MEK inhibitor, CI-1040. Neoplasia (2005) 1.18
Targeting gene expression selectively in cancer cells by using the progression-elevated gene-3 promoter. Proc Natl Acad Sci U S A (2005) 1.17
Targeting Ras signaling through inhibition of carboxyl methylation: an unexpected property of methotrexate. Proc Natl Acad Sci U S A (2003) 1.17
The isoprenoid substrate specificity of isoprenylcysteine carboxylmethyltransferase: development of novel inhibitors. J Biol Chem (2005) 1.15
Epstein-Barr virus LMP2A interferes with global transcription factor regulation when expressed during B-lymphocyte development. J Virol (2003) 1.14
Retracted siRNAs generated by recombinant human Dicer induce specific and significant but target site-independent gene silencing in human cells. Nucleic Acids Res (2003) 1.14
Activation of the extracellular signal regulated kinase (ERK) pathway in human melanoma. J Clin Pathol (2005) 1.13
Epstein-Barr virus LMP2A alters in vivo and in vitro models of B-cell anergy, but not deletion, in response to autoantigen. J Virol (2005) 1.13
Intrabodies based on intracellular capture frameworks that bind the RAS protein with high affinity and impair oncogenic transformation. EMBO J (2003) 1.12
Tumour prevention by a single antibody domain targeting the interaction of signal transduction proteins with RAS. EMBO J (2007) 1.11
KRAS mutation testing in metastatic colorectal cancer. World J Gastroenterol (2012) 1.11
Detection of K-Ras mutations in tumour samples of patients with non-small cell lung cancer using PNA-mediated PCR clamping. Br J Cancer (2009) 1.11
New insights into the actions of bisphosphonate zoledronic acid in breast cancer cells by dual RhoA-dependent and -independent effects. Br J Cancer (2003) 1.10
Understanding signaling cascades in melanoma. Photochem Photobiol (2007) 1.10
Novel signaling axis for ROS generation during K-Ras-induced cellular transformation. Cell Death Differ (2014) 1.08
Epidermal growth factor receptor and K-Ras in non-small cell lung cancer-molecular pathways involved and targeted therapies. World J Clin Oncol (2011) 1.08
Neurofibromin 1 (NF1) defects are common in human ovarian serous carcinomas and co-occur with TP53 mutations. Neoplasia (2008) 1.08
Therapeutic targeting of human hepatocyte growth factor with a single neutralizing monoclonal antibody reduces lung tumorigenesis. Mol Cancer Ther (2008) 1.07
Molecular mechanisms of metastasis in prostate cancer. Asian J Androl (2008) 1.06
SILAC-based phosphoproteomics reveals an inhibitory role of KSR1 in p53 transcriptional activity via modulation of DBC1. Br J Cancer (2013) 1.06
Targeting mutant KRAS for anticancer therapeutics: a review of novel small molecule modulators. J Med Chem (2013) 1.04
Protein kinase C delta is required for survival of cells expressing activated p21RAS. J Biol Chem (2007) 1.04
Multidimensional Screening Platform for Simultaneously Targeting Oncogenic KRAS and Hypoxia-Inducible Factors Pathways in Colorectal Cancer. ACS Chem Biol (2016) 1.03
Off-label use of cetuximab plus sorafenib and panitumumab plus regorafenib to personalize therapy for a patient with V600E BRAF-mutant metastatic colon cancer. Cancer Biol Ther (2013) 1.03
Mutation detection of epidermal growth factor receptor and KRAS genes using the smart amplification process version 2 from formalin-fixed, paraffin-embedded lung cancer tissue. J Mol Diagn (2010) 1.02
Cyclin D1 and mammary carcinoma: new insights from transgenic mouse models. Breast Cancer Res (2001) 1.00
Sensitive and specific detection of K-ras mutations in colon tumors by short oligonucleotide mass analysis. Nucleic Acids Res (2004) 0.99
The molecular basis of lung cancer: molecular abnormalities and therapeutic implications. Respir Res (2003) 0.97
Stimulatory effects of the multi-kinase inhibitor sorafenib on human bladder cancer cells. Br J Pharmacol (2010) 0.96
A mathematical model for microRNA in lung cancer. PLoS One (2013) 0.96
Genomic analysis of metastatic cutaneous squamous cell carcinoma. Clin Cancer Res (2015) 0.96
KRAS and BRAF mutations in 203 esophageal squamous cell carcinomas: pyrosequencing technology and literature review. Ann Surg Oncol (2012) 0.96
Molecular pathogenesis of endometrial and ovarian cancer. Cancer Biomark (2010) 0.95
High sensitivity EndoV mutation scanning through real-time ligase proofreading. Nucleic Acids Res (2004) 0.94
Biophysical mechanism for ras-nanocluster formation and signaling in plasma membrane. PLoS One (2009) 0.94
Regulation of ubiquitination-mediated protein degradation by survival kinases in cancer. Front Oncol (2012) 0.93
Phosphorylation of FADD by the kinase CK1α promotes KRASG12D-induced lung cancer. Sci Signal (2015) 0.93
A double-blind randomized discontinuation phase-II study of sorafenib (BAY 43-9006) in previously treated non-small-cell lung cancer patients: eastern cooperative oncology group study E2501. J Thorac Oncol (2012) 0.93
Computational studies of the farnesyltransferase ternary complex part I: substrate binding. Biochemistry (2005) 0.93
ALK gene amplification is associated with poor prognosis in colorectal carcinoma. Br J Cancer (2013) 0.92
Diabetes regulates small molecular weight G-protein, H-Ras, in the microvasculature of the retina: implication in the development of retinopathy. Microvasc Res (2008) 0.91
Driven to death: Inhibition of farnesylation increases Ras activity and promotes growth arrest and cell death [corrected]. Mol Cancer Ther (2010) 0.91
NRAS isoforms differentially affect downstream pathways, cell growth, and cell transformation. Proc Natl Acad Sci U S A (2014) 0.91
Stamping out RAF and MEK1/2 to inhibit the ERK1/2 pathway: an emerging threat to anticancer therapy. Oncogene (2015) 0.90
Proteomic profile of KSR1-regulated signalling in response to genotoxic agents in breast cancer. Breast Cancer Res Treat (2015) 0.90
Therapeutic implications of targeting the PI3Kinase/AKT/mTOR signaling module in melanoma therapy. Am J Cancer Res (2012) 0.90
Prognostic significance of TRAIL death receptors in Middle Eastern colorectal carcinomas and their correlation to oncogenic KRAS alterations. Mol Cancer (2010) 0.90
MTH1 expression is required for effective transformation by oncogenic HRAS. Oncotarget (2015) 0.90
RAS promotes tumorigenesis through genomic instability induced by imbalanced expression of Aurora-A and BRCA2 in midbody during cytokinesis. Int J Cancer (2013) 0.89
Genetic alterations in pancreatic cancer. World J Gastroenterol (2007) 0.89
Vitamin E analogues as inducers of apoptosis: structure-function relation. Br J Cancer (2003) 0.89
Molecularly targeted therapies for malignant gliomas. Mol Med (2009) 0.89
Epigenetic regulation in adult stem cells and cancers. Cell Biosci (2013) 0.88
Role of reactive oxygen species in proapoptotic ability of oncogenic H-Ras to increase human bladder cancer cell susceptibility to histone deacetylase inhibitor for caspase induction. J Cancer Res Clin Oncol (2009) 0.88
Intrinsic resistance to selumetinib, a selective inhibitor of MEK1/2, by cAMP-dependent protein kinase A activation in human lung and colorectal cancer cells. Br J Cancer (2012) 0.88
Oncolytic virotherapy for pancreatic cancer. Expert Rev Mol Med (2011) 0.88
Computational studies of the farnesyltransferase ternary complex part II: the conformational activation of farnesyldiphosphate. Biochemistry (2007) 0.87
Importance of molecular features of non-small cell lung cancer for choice of treatment. Am J Pathol (2011) 0.86
Molecular targets for tumor radiosensitization. Chem Rev (2009) 0.86
MKK7 and ARF: new players in the DNA damage response scenery. Cell Cycle (2014) 0.86
Peptide bicycles that inhibit the Grb2 SH2 domain. Chembiochem (2012) 0.85
Reversal of aberrant cancer methylome and transcriptome upon direct reprogramming of lung cancer cells. Sci Rep (2012) 0.85
Finding a needle in the haystack: computational modeling of Mg2+ binding in the active site of protein farnesyltransferase. Biochemistry (2010) 0.85
H-Ras increases urokinase expression and cell invasion in genetically modified human astrocytes through Ras/Raf/MEK signaling pathway. Glia (2008) 0.85
α-Lipoic acid suppresses migration and invasion via downregulation of cell surface β1-integrin expression in bladder cancer cells. J Clin Biochem Nutr (2013) 0.84
The effect of the farnesyl protein transferase inhibitor SCH66336 on isoprenylation and signalling by the prostacyclin receptor. Biochem J (2005) 0.84
Growth inhibitory effect of wild-type Kras2 gene on a colonic adenocarcinoma cell line. World J Gastroenterol (2007) 0.84
Dual modulation of JNK and Akt signaling pathways by chaetoglobosin K in human lung carcinoma and ras-transformed epithelial cells. Invest New Drugs (2012) 0.83
Cytotoxic activity of Apomine is due to a novel membrane-mediated cytolytic mechanism independent of apoptosis in the A375 human melanoma cell line. Invest New Drugs (2006) 0.83
Acute sensitivity of the oral mucosa to oncogenic K-ras. J Pathol (2011) 0.83
Racial and Ethnic Differences in the Epidemiology and Genomics of Lung Cancer. Cancer Control (2016) 0.82
BRAF in Melanoma: Pathogenesis, Diagnosis, Inhibition, and Resistance. J Skin Cancer (2011) 0.82
Polyisoprenylated methylated protein methyl esterase is both sensitive to curcumin and overexpressed in colorectal cancer: implications for chemoprevention and treatment. Biomed Res Int (2013) 0.82
The cell cycle regulator ecdysoneless cooperates with H-Ras to promote oncogenic transformation of human mammary epithelial cells. Cell Cycle (2015) 0.82
Current and future trials of targeted therapies in cutaneous melanoma. Adv Exp Med Biol (2013) 0.81